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Abstract
Background
Chronic widespread muscoloskeletal pain (CWP) is prevalent in the general population and
associated with high health care costs, so understanding the risk factors for chronic pain is
important for both those affected and for society. In the present study we investigated the
underlying etiological structure of CWP to understand better the association between the
major clinical features of fatigue, depression and dihydroepiandrosterone sulphate
(DHEAS) using a multivariate twin design.
Methodology/Principle Findings
Data were available in 463 UK female twin pairs including CWP status and information on
depression, chronic fatigue and serum DHEAS levels. High to moderate heritabilities for all
phenotypes were obtained (42.58% to 74.24%). The highest phenotypic correlation was
observed between fatigue and CWP (r = 0.45), and the highest genetic correlation between
CWP and fatigue (rg = 0.78). Structural equation modeling revealed the AE Cholesky model
to provide the best model of the observed data. In this model, two additive genetic factors
could be detected loading heavily on CWP—A2 explaining 40% of the variance and A3 20%.
The factor loading heaviest on DHEAS showed only a small loading on the other phenotypes
and none on fatigue at all. Furthermore, one distinct non-shared environmental factor loading
specifically on CWP—but not on any of the other phenotypes—could be detected suggesting
that the association between CWP and the other phenotypes is due only to genetic factors.
Conclusions/Significance
Our results suggest that CWP and its associated features share a genetic predisposition
but that they are relatively distinct in their environmental determinants.
PLOS ONE | DOI:10.1371/journal.pone.0140289 November 24, 2015 1 / 14
a11111
OPEN ACCESS
Citation: Burri A, Ogata S, Livshits G, Williams F
(2015) The Association between Chronic Widespread
Musculoskeletal Pain, Depression and Fatigue Is
Genetically Mediated. PLoS ONE 10(11): e0140289.
doi:10.1371/journal.pone.0140289
Editor: Dmitri Zaykin, NIH - National Institute of
Environmental Health Sciences, UNITED STATES
Received: June 23, 2015
Accepted: September 23, 2015
Published: November 24, 2015
Copyright: © 2015 Burri et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Individual level
genotype and phenotype data from TwinsUK are not
permitted to be shared or deposited due to the
original consent given at the time of data collection.
However, access to genotype and phenotype data
can be applied for through the TwinsUK data access
committee. For information on access and how to
apply, visit http://www.twinsuk.ac.uk/data-access/
submission-procedure/.
Funding: This work was supported by the Wellcome
Trust; European Community’s Seventh Framework
Programme (FP7/2007-2013). The study also
receives support from the National Institute for Health
Introduction
Chronic widespread musculoskeletal pain (CWP) is defined as “pain on the left side of the
body, pain on the right side of the body, pain above the waist, pain below the waist and axial
skeletal pain (cervical spine or anterior chest or thoracic spine or low back) for at least 3
months” [1]. It represents a key feature of the fibromyalgia (FM) syndrome which has a
reported prevalence in the general population of approximately 15% [2,3]. In addition, high
comorbidity of CWP with conditions such as chronic fatigue syndrome, headache, depression,
and anxiety have been reported [4,5]. CWP not only causes profound individual suffering and
disability in activities of daily living but is also associated with high health care utilization and
increased health care costs [6]. Knowledge about the causes of CWP remains very limited but
current research suggests that the pathology and its somatic expression appear to be influenced
by genetic susceptibility and a variety of behavioral and psychosocial factors [7–9].
Quantitative and molecular genetic studies have provided consistent evidence for a genetic
influence on CWP (heritabilities of up to 58%) and for a common genetic basis in multisite
musculoskeletal pain [9,10–11]. Multivariable twin analyses investigating the importance of
genetic factors on the etiology of CWP and its comorbidites (e.g., chronic fatigue, irritable
bowel, anxiety and depression) have found evidence of unmeasured genetic and family envi-
ronmental factors underlying the co-occurrence of all these conditions [12–13]. A recent study
conducted by our research group (N = 3,266 female twins) explored the etiological structure of
CWP and its psycho-affective correlates and found that the co-occurrences between CWP,
anxiety, depression, emotional instability, and emotional intelligence could be explained by
two distinct latent factors– a more sensory and a more affective one—which show a common,
genetically determined underlying factor [11]. In summary, these findings point towards a het-
erogeneous etiological structure underlying CWP and its correlates, wherein physical, psychiat-
ric and premorbid affective traits influence the development of the disorder.
Despite recent research efforts, our understanding of the commonly reported features of
CWP such as fatigue, and/or symptoms of depression remains limited [14–15]. Fatigue in
CWP patients has been described as chronic, abnormal and non-functional, and of complex or
unknown etiology [16]. Reciprocal relationships between chronic fatigue, depression, physical
incapacity and CWP have been suggested leading to a vicious cycle of poor mental and physical
health [17]. Expression and levels of these CWP-associated symptoms seem to be influenced
by hormonal alterations. The observations that prevalence of such symptoms is greater in
women than men, and that the incidence of early menopause may be higher in FM patients
compared to rheumatoid arthritis patients and healthy controls [18], has lead to the hypothesis
that sex hormones may be involved in the pathogenesis of FM [19–20]. This is supported by
the fact that women report an increase and worsening of generalized pain and fatigue when
undergoing menopause [21,18]. Furthermore, some studies of women with FM show a correla-
tion between low cortisol levels, pain and depression [22–23]. In this context, dehydroepian-
drosterone sulfate (DHEAS)—an endogenous steroid hormone,—has been associated with the
maintenance of FM symptomatology [21,22,24]. DHEAS directly influences testosterone pro-
duction in the adrenal gland and the levels of androgens have been shown to decrease in pre-
and postmenopausal women and to be inversely related to perceptions of stress and cortisol
levels [21]. In a small cross sectional observational study of 17 women with FM and 19 healthy
controls, Pegado and colleagues, for example, observed a tendency towards lower DHEAS lev-
els in the FM group and a positive correlation between DHEAS and the pressure pain and tol-
erance [21]. Our recent work, using extensive and agnostic metabolomics screening in
TwinsUK suggests that several DHEAS –related hormones, namely, androsterone sulfate,
epiandrosterone sulfate, and DHEAS are strongly associated with CWP variation, in both the
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twin sample and independently replicated in a second group, the KORA study [25]. We found
that the risk of CWP increased with a decrease in these hormones levels, and that with the latter
appear to fall secondary to CWP rather than lying within the causal pathway to CWP. Multi-
variate genetic twin analyses were conducted to understand better the correlational structure
and underlying etiological mechanisms in CWP and its common related biopsychological fea-
tures. More specifically, the contributions of depression, fatigue, and serum DHEAS concentra-
tions measured by automated electrochemiluminescence immunoassay in CWP disease
expression were investigated by taking into account the inter-correlations among the pheno-
types using a sample of unselected British female twin volunteers from the TwinsUK register.
Material and Methods
Participants
Participants were from the NIHR BRC BioResource TwinsUK, a nation-wide registry of female
(83%) and male volunteer twins in the United Kingdom, with about 12,000 registered individu-
als [26,27]. The registry has an equal number of monozygotic (MZ) and dizygotic (DZ) twins
which are predominantly middle-aged and older. The registry was started in 1993 and over the
last 22 years extensive questionnaire, biomedical and clinical data have been collected. The pri-
mary focus of study has been the genetic basis of healthy aging processes and complex diseases,
including cardiovascular, metabolic, musculoskeletal, and ophthalmologic disorders. For more
detailed information regarding the cohort and the recruitment process see [26]. The cohort has
been shown to be generalizable to UK population singletons for a wide variety of musculoskele-
tal, CVD, and metabolic traits, as well as lifestyle factors [28]. The present study received
approval from the ethics committee at St. Thomas´ Hospital, and written consent was obtained
before data collection. The research followed the tenets of the Declaration of Helsinki.
The study sample included all individuals who had CWP, and information on the other
phenotypes of interest available. CWP data were available for a total of 3,266 female individu-
als. This study represents a sub-study of a larger project focusing on the epidemiology of CWP
in females, hence no information regarding CWP was obtained for males at this point. Match-
ing information on fatigue, depression and DHEAS were available for 463 twin pairs, compris-
ing 219 MZ pairs, and 244 DZ pairs. Twin pairs where one twin had data but the co-twin did
not have data (treated as missing values) were also included [29]. Individuals having conditions
with known somatic causes of pain such as fracture, cancer, rheumatoid arthritis, and defined
neuropathic causes of pain were excluded from the study. Zygosity of twins was assigned using
a standard questionnaire and was confirmed with multiplex DNA genotyping and, more
recently, genetic association markers on DNA obtained from venous blood samples.
Measures
CWP. The London Fibromyalgia Epidemiology Symptom Screening Questionnaire
(LFESSQ) was used to screen for self-reported CWP [30]. This 6-item questionnaire was origi-
nally designed to screen for FM in the general population and in specific patient groups and
includes 4 items relating to widespread pain, and 2 items relating to fatigue. For the assessment
of CWP, the four items pertaining to the “pain subscale” and asking about pain left and right of
body and above and below diaphragm lasting at least 7 days in the previous 3 months were
considered. In order to classify an individual as having CWP, participants had to respond “yes”
to all four pain items with either both a right- and left-side positive response or a positive
response for pain at both sides. The utility of this phenotype assessment is supported by the
contribution these twins have made to previous studies, such as the genome-wide association
Twin Analyses of CWP
PLOSONE | DOI:10.1371/journal.pone.0140289 November 24, 2015 3 / 14
meta-analysis conducted by Peters and colleagues [31] or the twin studies by Burri and col-
leagues [32,33].
CWP Related Biopsychological Features. Blood samples were collected from each of the
study participants either after overnight fasting or non-fasting. Serum concentrations of
DHEAS were measured by automated electrochemiluminescence immunoassay “ECLIA”
(Roche Diagnostics, Mannheim, Germany). The intra- and interassay coefficients of variability
were 2.3% and 4.4%, respectively.
Fatigue can be distinguished as peripheral muscle fatigue and central fatigue and previous
reports have suggested that both subjective ratings and objective evaluation of fatigue measures
(e.g., using surface electromyography) should be assessed [34]. However, this is relatively
impractical for population samples and because subjective experiences might have a higher rel-
evance for subjective well-being and impairment of quality of life, only subjective ratings of
perceived fatigue were considered. For this, 2 items from the LFESSQ relating to fatigue were
used to assess chronic fatigue. Screening positive for chronic, debilitating fatigue required a
“yes” response to both fatigue items.
The diagnosis of depression was obtained using the depression module of the Composite
International Diagnostic Interview (CIDI) questionnaire according to the DSM-IV criteria for
major depression disorder (MDD) and was handled as a dichotomous variable in all analyses
[32,35]. The CIDI interview included the three STEM questions (e.g. “Have you ever in your
life had a period lasting several days or longer when most of the day you felt sad, empty or
depression?”). Participants positively answering one of the three questions were given the
depression module to fill in and were classified as having depression if five out of nine depres-
sive symptoms persisting for two weeks or longer were present. Symptoms included dysphoric
mood or anhedonia, weight gain/loss or appetite disturbance, insomnia or hypersomnia, psy-
chomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or exces-
sive guilt, diminished ability to concentrate or think clearly, and recurrent thoughts of death or
suicide [35].
Twin Analyses
The classical twin design was used to conduct univariate and multivariate analyses of genetic
and environmental influences on the variance and covariance of CWP, fatigue, depression and
DHEAS. The twin method is based on the assumption that twins reared together resemble
each other due to the additive effects of shared genes or shared environmental factors. MZ
twins further share around 100% of all segregating genes whereas DZ twins share—on average
—50% of their segregating alleles. For both univariate and multivariate analyses, structural
equation modeling with full information maximum-likelihood estimation was used and phe-
notypic variance and covariance was decomposed into additive genetic (A), dominant genetic
(D), shared environmental (C), and non-shared environmental (E) etiologies [36–39]. All
observed variables were adjusted for age in the models, and standardized path coefficients with
the 95% confidence intervals (CIs) were obtained. To handle missing values, full information
maximum likelihood was used [29]. Under a missing at random assumption, full information
maximum likelihood was able to give preferred parameter estimates [29]. Data handling and
all statistical analyses were conducted using R statistical software, version 3.1.2 (R Core Team,
2014). Genetic analyses were conducted using the R package “OpenMx”.
For the calculation of univariate heritabilities of each phenotype, structural equation model-
ing (SEM) was used. Univariate analyses were extended to multivariate twin analyses to investi-
gate the relative importance of genetic and environmental factors in the phenotypic
associations between our four phenotypes of interest—DHEAS, fatigue, depression, and CWP.
Twin Analyses of CWP
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The multivariate genetic model estimates genetic and environmental mediation of the pheno-
typic correlation between the phenotypes of interest. Central to the analysis is the genetic corre-
lation, which is the extent to which genetic effects on one variable are correlated with genetic
effects on another variable, indicating pleiotropy. First, MZ and DZ cross-trait cross-twin cor-
relations (CTCT) were examined. A CTCT correlation is a correlation between trait A in a
twin and trait B in the co-twin. The phenotypic associations between the observed variables
were partly decomposed into A and D if the phenotypic associations between the observed var-
iables were higher in MZ compared to DZ twin pairs. In cases where the phenotypic associa-
tions in MZ twin pairs were similar or equal to those in DZ twins, the phenotypic associations
were decomposed into C. In cases where no phenotypic associations between the observed vari-
ables within a twin pair could be detected, the phenotypic associations were decomposed into
E.
Next to indicate the best fitting, and theoretically most acceptable and parsimonious model,
the following four-step analyses were conducted. First, the full ACE and ADE Cholesky models
were compared with the fully saturated model since C and D cannot be estimated in the same
model [37,38]. Model comparison also allows testing of the assumption that mean and variance
of each observed phenotype is equal across twin order and zygosity—a prerequisite for multi-
variate twin modeling [38]. In the fully saturated model, the variance-covariance matrix was
treated as a free parameter equal to the sample variance-covariance matrix. In the full Cholesky
model, mean and variance of each observed phenotype were modeled to be equal across twin
order and zygosity [37]. Thus, the assumption was met if the log likelihood ratio test showed
no significant differences between the full Cholesky model and the fully saturated model [37].
Second, the full ACE or ADE Cholesky model was compared to the AE Cholesky model to test
whether elimination of C or D factors was possible.
The Cholesky decomposition provides the correlations between the four independent
genetic and environmental factors and decomposes the variance of the four phenotypes into
distinct additive genetic and distinct non-shared environmental effects, providing the fullest
potential explanation of the data. Here, the expected variance-covariance matrix is parameter-
ized in terms of n (= number of variables) latent factors. The independent pathway model is a
submodel of the Cholesky model. It generally tests whether the covariance between the four
phenotypes can be explained by a single shared genetic and shared environmental factor. An
independent pathway model would suggest that all phenotypes share common etiological fac-
tor [37]. A common pathway model suggests that a latent phenotype underlies the four pheno-
types, which in turn is influenced by shared genetic and shared unique environmental factors
[37].
Third, the AE Cholesky model was compared to an AE independent pathway model and an
AE common pathway model. Fourth, on the basis of the most plausible AE model among the
AE Cholesky, AE independent pathway, and AE common pathway models, we made sub-mod-
els eliminating parameters and latent variables and compared these sub-models to the full ACE
or ADE Cholesky model. Model comparisons were carried out on the basis of the likelihood
ratio test and Akaike information criterion (AIC), with a smaller AIC indicating a better bal-
ance of model fit to the observed data and parsimony [38].
Results
The sample selected from TwinsUK was entirely female. The mean age was 58.4 years (SD 11.1,
range 26 to 82 years; Table 1). In this sample the prevalence of CWP was 19.6% and of depres-
sion was 30.1%. No significant differences in the phenotypes of interest could be detected
between MZ and DZ twins (Table 1).
Twin Analyses of CWP
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Phenotypic Correlation and Phenotypic Heritability
First, the phenotypic correlations and CTCT correlations between the four phenotypes were
examined. The highest phenotypic correlation was seen between fatigue and CWP (r = 0.45)
(Table 2). DHEAS showed a significant negative correlation with CWP (-0.23) but was not cor-
related with either depression or fatigue. There were statistically significant correlations
between all the other phenotypes. High to moderate heritabilities for all phenotypes were
obtained, with DHEAS showing the highest estimate (74.2%; 95% CI 65.8% to 80.5%), followed
by CWP (70.8%; 95% CI 44.1% to 87.8%), depression (49.9%; 95% CI 19.0% to 74.1%) and
fatigue (42.6%; 95% CI 24.7% to 57.0%). Next, the CTCT correlations were calculated to esti-
mate the extent to which the phenotypic correlations between the four phenotypes are medi-
ated by genetic and environmental influences. Analyses revealed that CTCT correlations were
generally higher in MZ compared to DZ twins, indicating that the phenotypic covariance
among the three symptoms is largely due to shared genetic factors. In other words, higher
CTCT correlations in MZ twins suggest that genetic factors underlie the correlation between
the four phenotypes (Table 3).
Multivariate Genetic Analyses
Multivariate genetic analyses were conducted to investigate the genetic and environmental
structure among DHEAS, fatigue, depression, and CWP. Model comparison among the fully
saturated model, full ACE Cholesky model and full ADE Cholesky model were performed
Table 1. Characteristics of the study group; overall and by zygosity.
Overall MZ DZ P-value
Age 58.39 (11.08) 26–82 58.63 (11.50) 26–82 58.14 (10.67) 27–80 0.602
DHEAS (umol/L) 3.10 (1.93) 0.06–12.23 3.16 (2.00) 0.13–12.23 3.03 (1.87) 0.06–10.95 0.683
Fatigue 1.55 (1.29) 0–4 1.56 (1.27) 0–4 1.55 (1.31) 0–4 0.234
CWP 126 (19.62) 62 (19.5) 64 (19.75) 0.535
Depression 193 (30.06) 97 (30.5) 96 (29.62) 0.552
Age, DHEAS, fatigue are given as mean (SD), range; CWP and Depression as N = sample size (%)
Overall sample = 642 individuals, 463 full pairs. MZ = 318 individuals, 219 full pairs; DZ = 324 individuals, 244 full pairs.
No signiﬁcant differences between the MZ and DZ could be detected.
MZ = monozygotic twins; DZ = dizygotic twins; CWP = chronic widespread pain; DHEAS = dehydroepiandrosterone sulfate.
doi:10.1371/journal.pone.0140289.t001
Table 2. Phenotypic associations between variables of interest (N = 642 individuals).
DHEAS Depression Fatigue CWP
DHEAS 1
Depression -0.020 1
Fatigue 0.055 0.286** 1
CWP -0.226** 0.321** 0.454** 1
CWP = chronic widespread pain; DHEAS = dehydroepiandrosterone sulfate.
Pearson correlations between continuous variables (DHEAS and fatigue); tetrachoric correlations between dichotomous variables (depression and CWP);
biserial correlations between continuous and dichotomous variables.
* p<0.05;
** p<0.01
doi:10.1371/journal.pone.0140289.t002
Twin Analyses of CWP
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(Table 4). Of the full models, the ADE Cholesky model provided the best balance of fit and par-
simony of the observed data, based on the AIC. Subsequently, model comparison among the
full ADE Cholesky model, the AE Cholesky model, the AE independent pathway models, and
the AE common pathway models were performed (Table 5). On the basis of the log likelihood
ratio test, an AE Cholesky model provided the best fitting and most parsimonious model
(Table 5; Fig 1). According to that model, the variance and covariance in the phenotypes was
decomposed into three distinct additive genetic factors and four distinct non-shared environ-
mental factors. We calculated percentage of genetic variance in phenotypic variance of each
variable (100 x genetic variance/ phenotypic variance). Two additive genetic factors loading
heavily on CWP could be detected (A2 explaining 40% of the phenotypic variance and A3
20%), with A2 also explaining 40% of phenotypic variance in fatigue and A3 explaining 31% of
phenotypic variance in depression. The factor loading most heavily on DHEAS showed only
small loads on the other phenotypes and no load at all on fatigue (Fig 1). Similarly, we calcu-
lated the percentage of non-shared environmental variance in phenotypic variance of each var-
iable (100 x non-shared environmental variance/ phenotypic variance). The non-shared
environmental factor explaining 20% of phenotypic variance in DHEAS did not show any
effect on fatigue and CWP. Interestingly, only one distinct non-shared environmental factor
loading on CWP could be detected, explaining 34% of phenotypic variance in CWP, hence sug-
gesting that the association between CWP and the other phenotypes is due to only genetic fac-
tors (Fig 1).
Table 3. Cross twin cross trait correlations (CTCTwith 95% confidence interval) between the traits of interest.
CTCT (95%CI)
DHEAS Fatigue Depression CWP
DHEAS 0.805 (0.794 to 0.850)
0.501 (0.373 to 0.611)
Fatigue 0.080 (-0.071 to 0.228) 0.513 (0.388 to 0.619)
-0.033 (-0.204 to 0.141) 0.094 (-0.088 to 0.270)
Depression -0.055 (-0.198 to 0.091) 0.234 (0.083 to 0.375) 0.597 (0.495 to 0.686)
-0.082 (-0.242 to 0.081) -0.090 (-0.264 to 0.090) -0.067 (-0.231 to 0.101)
CWP -0.235 (-0.363 to -0.098) 0.316 (0.175 to 0.445) 0.353 (0.220 to 0.473) 0.717 (0.642 to 0.779)
-0.195 (-0.341 to -0.040) 0.224 (0.054 to 0.382) 0.134 (-0.028 to 0.288) 0.376(0.235 to 0.502)
MZ CTCTs are displayed in the upper row, DZ CTCTs in the lower row.
MZ = 219 pairs; DZ = 244 pairs
CWP = chronic widespread pain; DHEAS = dehydroepiandrosterone sulfate; MZ = monozygotic; DZ = dizygotic.
doi:10.1371/journal.pone.0140289.t003
Table 4. Results of the model comparison between the fully saturated, the full ACE Cholesky, and the full ADE Choleskymodeling.
Difference of log likelihood Difference of degree of df P-value AIC
The fully saturated model Base Base Base -394.675
The full ACE Cholesky model 59.013 58 0.438 -451.661
The full ADE Cholesky model 57.562 58 0.491 -453.112
MZ (N = 219 pairs) and DZ (N = 244 pairs).
A = additive genetic factors; C = shared environmental factors; D = non-additive genetic factors; E = non-shared environmental factors; AIC = Akaike
information criterion; df = degree of freedom; MZ = monozygotic; DZ = dizygotic.
The most suitable model by AIC is the ADE Cholesky model (in bold)
doi:10.1371/journal.pone.0140289.t004
Twin Analyses of CWP
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Overall fatigue, depression and DHEAS accounted for 65.7% of the variance in CWP with
the Cholesky model revealing that the genetic variance of CWP was explained by the covaria-
tion of the three phenotypes, with 9% shared with DHEAS, 61% with fatigue, and 30% with
depression. The highest non-shared environmental correlations (i.e., correlations measure
Table 5. Results of the model comparison among the full ADE Cholesky model and sub-models.
Difference of log
likelihood
Difference of
df
P-
value
AIC
Full ADE Cholesky model Base Base Base -453.112
AE Cholesky model 3.959562 10 0.949 -469.153
AE independent pathway model with one genetic or environmental latent variables
common to observed variables
19.69748 14 0.139 -461.415
AE common pathway model with one phenotypic latent variables common to observed
variables
25.41869 17 0.085 -461.694
AE independent pathway model with two genetic or environmental latent variables
common to observed variables
13.45777 6 0.036 -451.655
AE common pathway model with two phenotypic latent variables common to observed
variables
15.53236 10 0.113 -457.58
Cholesky AE model (see Fig 1) 10.99799 17 0.856 -476.114
Sample: MZ (N = 219 pairs) and DZ (N = 244 pairs).
A = additive genetic factors; C = shared environmental factors; D = non-additive genetic factors; E = non-shared environmental factors; AIC = Akaike
information criterion; df = degree of freedom; MZ = monozygotic; DZ = dizygotic.
The most suitable model is shown in bold, having the lowest AIC
doi:10.1371/journal.pone.0140289.t005
Fig 1. Path diagram of the best fitting AE Cholesky model depicting the sources of covariance between CWP, DHEAS, depression, and fatigue.
The variance of 219 monozygotic (MZ) and 244 dizygotic (DZ) twin pairs was decomposed into two additive genetic (A1–A2) and an unshared environmental
(E1) factor. Standardized factor loadings with 95% confidence interval (CI) and variances for the phenotypes are displayed.
doi:10.1371/journal.pone.0140289.g001
Twin Analyses of CWP
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shared by the variables´ random environmental effects, with respect to the individual) could be
observed between depression and DHEAS (rE = 0.49), followed by depression and fatigue (rE =
0.38; Table 6). None of the other phenotypes correlated environmentally with each other. Fur-
thermore, high genetic correlation between CWP and fatigue (rG = 0.78) and depression (rG =
0.62) could be detected, as well as more moderate genetic correlations between CWP and
DHEAS (rG = -0.29) and between DHEAS and depression (-0.43; Table 6).
Discussion
Although the co-occurrence of CWP with symptoms of fatigue and depression has been
reported frequently, the etiology of each symptom and how they relate to one another remains
poorly understood. In the present study we used the classical twin design to investigate the link
between CWP and its biophysiological correlates and found a strong association between
fatigue and CWP, with genetic factors of chronic fatigue explaining 60.8% of genetic variance
of CWP. Additionally we report evidence for a strong genetic link between CWP and fatigue,
as well as depression. The association between DHEAS and fatigue reported previously in
small clinical studies was not confirmed in our study. However, moderately strong association
between DHEAS and CWP and DHEAS and depression were observed. In addition, one dis-
tinct non-shared environmental factor loading specifically on CWP—but not on any of the
other phenotypes—was found, suggesting that the association between CWP and the other
phenotypes is mediated by genetic factors alone. These findings provide further insights into
the etiologic nature of CWP and its clinical features. One might speculate that the environmen-
tal factor might represent adverse early life events such as maternal separation but we are not
in a position to test this hypothesis at present.
Heritability of CWP and its Clinical Features
The best fitting models from the univariate analyses showed that all phenotypes were heritable
(h2 ranging from 42.6% to 74.2%), and comprised only A and E factors (including measure-
ment error) to explain phenotypic variance. The highest heritability was found for DHEAS
with an estimate of 74.2%. Biological and anatomical phenotypes generally show higher genetic
influences as compared to psychological or behavioral traits. Previous reports, such as the
study by Yildiz or Nestler and colleagues reported lower heritabilities of DHEAS of 43% and
Table 6. Environmental and genetic correlations between the phenotypes of interest.
CTCT (95%CI)
DHEAS Fatigue Depression CWP
DHEAS 1
1
Fatigue 0 1
0 1
Depression -0.433 0 1
0.491 0.381 1
CWP -0.296 0.780 0.625 1
0 0 0 1
Estimates were derived from the best ﬁtting AE Cholesky model in MZ (N = 219 pairs) and DZ (N = 244 pairs).
Genetic correlations are displayed in the upper row, environmental correlations in the lower row
Abbreviations: CWP = chronic widespread pain; DHEAS = dehydroepiandrosterone sulfate; MZ = monozygotic; DZ = dizygotic.
doi:10.1371/journal.pone.0140289.t006
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60% respectively [40,41]. Similarly, the heritability of CWP in the present study (70.83%) was
higher than previously reported estimates (e.g. 58% and 54% by Kato et al. and Markkula et al.,
respectively) [9,42]. These differences might be the result of restricted sample size and/or un-
adjustment for potential additional covariates. For example, in the previous study from Twin-
sUK a significant correlation of CWP with fat mass was seen using a slightly different sample
[25]. In terms of chronic fatigue, the estimated heritability of 42.6% matched previous reports
(ranging from 30% to 51%). Overall, and in line with previous reports, we found no evidence of
environmental influences shared by siblings on individual differences in any of the phenotypes.
Instead, the type of environmental influence that was important was entirely of a non-shared
nature and, in case of CWP and DHEAS, considerably smaller than the genetic effects.
Common Genetic and Specific Environmental Influences on the
Covariation between CWP, Fatigue and Depression
Although exploration of the correlates of CWP has been the target of substantial epidemiologic
research in the past, there have been very few multivariate studies especially using genetically
sensitive designs. The genetic correlation results from our genetic analyses describe the extent
to which genetic effects on one variable are correlated with genetic effects on another. Genetic
correlation between CWP and fatigue was 0.78 and between CWP and depression was 0.63.
There was no evidence of a common non-shared environmental etiology to CWP or any of the
other phenotypes. Overall these findings suggest that two of the major features of CWP—
chronic fatigue and symptoms of depression—are related to CWP largely for genetic reasons,
thus we tentatively speculate that they may not be consequences of the chronic pain condition
per se but rather symptomatologically related. In other words, the chronic fatigue often
observed in CWP patients may in fact not be due to the general effect that chronic pain can
have on energy levels or due to side-effects of medication but seem to be part of the clinical syn-
drome. This is further supported by the fact that fatigue accounted for a larger proportion of
the genetic variance in CWP (61%) than any of the other phenotypes (30% explained by
depression and only 9% by DHEAS). Again, we reiterate that replication of the present findings
in an independent sample will add further weight to the findings.
Our genetic modeling supports previous findings which illustrate that features of CWP are
relatively etiologically distinct from each other—particularly in terms of environmental factors.
This is not only supported by the heterogeneity in phenotype specific non-shared environmen-
tal factors that we detected but also by the finding that both the common and independent
pathway models (both assuming a common underlying structure to the phenotypes, either a
latent phenotype or a unanimously shared overarching etiologic structure) provided poorer fits
to the data than the Cholesky model, indicating that the different CWP features are not
explained by a single underlying disease entity.
CWP-Related Chronic Fatigue and DHEAS Dysregulation
Dysregulation of DHEAS has been proposed to play an etiologic role in the maintenance of FM
symptomatology by modulating inflammatory responses [43,44]. The endogenous steroid hor-
mone has further been ascribed a pivotal role in fatigue, general well-being, and depression
[45,46]. Study results, however, are fairly inconsistent. Numerous placebo controlled, random-
ized clinical trials have investigated the use of DHEA substitution in a variety of clinical popu-
lations using fatigue as the main outcome measure. While some reported a positive effect on
psychological well-being, mood, and fatigue [47–49], others were unable to detect such an
influence [45,50–51]. Interestingly, a strong placebo effect could be observed in many of the
unsuccessful clinical DHEAS trials, suggesting a potential role of psychotherapy to be able to
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provide considerable benefits in treating chronic fatigue in these patients. We did not observe a
link between DHEAS and fatigue in our study, thus mirroring the discrepant study reports that
have failed to produce consistent proof of association of DHEAS in chronic fatigue (e.g., [48–
49,52]). Here, it has to be noted that the majority of the past studies were small while here we
report findings in one of the largest samples so far. Many studies have investigated the etiology
and pathogenesis of chronic fatigue, and different biological mechanisms have been proposed
in the past, with DHEAS and the HPA axis being one candidate. Nowadays, the etiology and
pathogenesis is generally believed to be multifactorial [47], with symptom explanations being
sought in viral infections, immune dysfunction, neuroendocrine responses, genetic factors, per-
sonality, (neuro)psychological processes, etc.—to name a few [53]. It has been further proposed
that the development of the symptoms is due to distinctive categories of predisposing, precipi-
tating, and perpetuating factors and that the presence of one or more factors is conditional but
insufficient [54]. Given the absence of a link between DHEAS and fatigue in our study—one of
the largest to date—it is likely that the mechanisms promoting symptoms of fatigue in CWP
and FM are unrelated to the HPA axis and DHEAS dysregulation and that other sources– pos-
sibly psychological—have to be considered.
We observed moderate negative genetic associations between DHEAS and CWP and
DHEAS and depression. Here, the association of DHEAS and CWP was exclusively due to a
shared genetic basis, again suggesting—similar to CWP and fatigue—that the lower DHEAS
levels in individuals suffering from chronic pain are not a consequence of the condition but
may be even viewed and used as a potential CWP endophenotype or biomarkers in future stud-
ies [54,55].
Environmental Etiology
While the overall study goal was to describe the genetic landscape of CWP using a set of biop-
sychiological features, our results also inform on the environmental influences which sensitive
designs such as the twin model can help disentangle. Most notable is our finding of a specific
non-shared environmental factor explaining 34.3% of the variance in CWP that shows no
influence on any of the other CWP covariates. If the sources of the variance in CWP are indeed
environmental factors, the source of this influence would appear to be an especially good target
for intervention but more fine-grained studies will be needed to identify precise environmental
predictors.
Limitations
Some limitations should be noted. Our findings require independent replication to ensure that
they are generalisable to other populations. However, compared to the vast number of previ-
ously conducted studies—especially of a clinical nature—the sample size is good. Second, the
screening tool used in this study did not include a clinical evaluation of CWP; instead, presence
of CWP was determined using short, validated self-report questionnaire. This approach may
be variable with regard to adherence to a strict set of diagnostic criteria for CWP, thus our
results should be interpreted with this caution in mind. However, questionnaire-based screen-
ing has been suggested as useful in general population surveys, with high positive predictive
value and test-retest reliability [30]. Similarly, self-report was used to assess depression, rather
than relying on a clinical diagnoses. But because the questions assessing the various symptoms
were independent from each other, and the subjects were unaware of the hypothesis being
tested, the correlation among the phenotypes found in our study reflects real trait co-occur-
rence rather than an artifactual one resulting from overlapping definition criteria for depres-
sion, fatigue conditions, and CWP. Third, our analyses included female twins only and,
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therefore, results cannot be generalized to adult males. Sex differences in genetic and environ-
mental variances in CWP, depression and fatigue have previously been reported [56,57].
Fourth, the association between the symptoms may vary with age and although we controlled
for the main effects of age in structural equation modeling, extrapolation of the results to other
age groups is not possible and a longitudinal design will need to be employed to investigate
age-dependent phenotypic variation. Similarly, the higher prevalence of CWP and depression
found in our study compared to previous ones might be the result of the preponderance of
females of middle age in the TwinsUK registry. Finally, only one DHEAS sample per individual
for one time point was available. Two inherent difficulties with the study of hormones is their
variability over time and the determination of whether an effect is primary or secondary [58].
Hence, longitudinal studies should be conducted in the future.
Conclusions
In conclusion, our results suggest that the associations between CWP and fatigue and depres-
sion are due to shared genetic factors alone, indicating that neither the shared nor unshared
environments contribute to their co-occurrence. Similarly, a genetic relationship between
DHEAS and CWP and depression were found. We do not find an association between DHEAS
and fatigue. Overall, our findings support previous studies in that features of CWP such as
depression and fatigue are etiologically distinct from each other on an environmental level but
that they share a genetic base which accounts for their clinical co-occurrence. Our findings
highlight an avenue for future research that may provide additional utility in characterization
of the complex etiology and clinical presentation of CWP.
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